Most investors didn't find anything confusing about the statement that ALL ENDPOINTS WERE MET, nor with the supporting data that actually indicates patient IMPROVEMENT. There's been no history of Anavex misleading data of trial results, EVER... only positively successful outcomes in AD, PDD and RETT. There is absolutely no reason to doubt Anavex with its AD P2b/3 claims now either. The additional data will be confirmatory... especially the 50mg treatment arm.
No worries here... as I continue to add to my position at several manipulated dips.
Market Data 
Markets 
AI
